IDYA IDEAYA Biosciences, Inc.
Price Chart
Executive Summary
IDEAYA Biosciences filed a prospectus supplement on May 5, 2026, for an at-the-market (ATM) offering of up to $156.6 million in common stock, the remaining portion of a $350 million facility established in January 2024. The filing coincides with the same day's positive earnings release and clinical trial results. The offering is dilutive (~6.3% of market cap) but the company's strong cash position ($973M) and positive pipeline momentum may offset some negative sentiment.
Actionable Insight
Monitor the pace of ATM sales and any use-of-proceeds announcements. The offering may create near-term downward pressure due to dilution, but the strong cash position and positive clinical data provide a floor. Watch for potential acceleration of sales if the stock remains elevated post-earnings.
Key Facts
- Up to $156,552,996.81 in common stock remains available under the ATM facility (already sold $193,447,003.19)
- Stock price as of May 1, 2026: $28.19 per share
- Net tangible book value per share as of March 31, 2026: $10.67; dilution of $16.52 per share to new investors
- Company had ~$973 million in cash, cash equivalents, and marketable securities as of March 31, 2026
- Commission to Jefferies: up to 3.0% of gross proceeds
- Positive Phase 2/3 OptimUM-02 trial results announced on April 13, 2026, met primary endpoint
- Proceeds for general corporate purposes, including clinical development and potential commercialization
Financial Impact
Dilution of approximately $16.52 per share on the assumed $28.19 offering price; offering size ~6.3% of market cap
Risk Factors
- Continued dilution from ongoing ATM sales
- Potential overhang from future equity issuances
- Execution risk in commercialization with raised capital
Market Snapshot
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 424B5 Filing (Primary) | 0001193125-26-206788 |
| Document: d30692dexfilingfees.htm | 0001193125-26-206788 |
| Document: 0001193125-26-206788-index-headers.html | 0001193125-26-206788 |
| Document: 0001193125-26-206788-index.html | 0001193125-26-206788 |
| Document: 0001193125-26-206788.txt | 0001193125-26-206788 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
|
Jun 9, 2026
today
|
424B5
| $28.09 awaiting T+1 | awaiting T+1 | — | $31.48 (−12.09%) |
|
Jun 8, 2026
1d ago
|
424B5
| $31.54 awaiting T+1 | awaiting T+1 | — | $31.48 (+0.19%) |
|
Jun 3, 2026
6d ago
|
8-K
| $28.40 $29.22 | ▲ +2.89% | ▲ +2.49% | $31.48 (+10.85%) |
|
May 5, 2026
5w ago
|
8-K
| $28.74 $28.24 | ▼ −1.74% | ▼ −1.41% | $31.48 (+9.53%) |
|
May 5, 2026
5w ago
|
424B5
| $28.74 $28.24 | ▼ −1.74% | ▼ −1.41% | $31.48 (+9.53%) |
|
Apr 13, 2026
8w ago
|
8-K
| $32.82 $32.35 | ▼ −1.43% | ▼ −2.64% | $31.48 (−4.08%) |
|
Apr 9, 2026
8w ago
|
8-K
| $31.00 $30.50 | ▼ −1.61% | ▼ −1.55% | $31.48 (+1.55%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access